MyHeritage plans to offer Promethease free of charge through the end of this year and to maintain SNPedia as a free resource for academic and non-profit users.
By sequencing an Indus Valley Civilization representative and related individuals, investigators learned more about the South Asian ancestry, farming history, and languages.
In an abstract to be presented at ASHG, Baylor Genetics researchers will discuss how Emedgene's AI-driven platform helped them streamline and standardize sequencing review.
Researchers identified tumor microbe and immune differences in tumor samples from pancreatic ductal adenocarcinoma patients with exceptionally long survival.
In PNAS this week: intronic STAT3 splice site linked to autosomal dominant primary immunodeficiency condition, human B lymphocyte changes following Epstein-Barr virus exposure, and more.
The company will market Inivata's InVision liquid biopsy assays to insured and self-pay patients across the region.
In PLOS this week: alternatively spliced form of FBXO38 contributes to chronic obstructive pulmonary disease, evolution of the avian influenza virus H9N2, and more.
By sequencing 10 Bronze, early Iron, and late Iron Age individuals, researchers retraced ancestry patterns at a Philistine port city in present-day Israel.
At the WIN Symposium, a researcher from Sheba Medical Center discussed ongoing efforts to develop a 22-gene signature for predicting brain metastasis in NSCLC.
Variantyx, a 2014 spinout from Tel Aviv University that is based in Framingham, Massachusetts, provides clinical genomic testing for screening and rare disease diagnostics.
Retraction Watch reports that a paper was pulled because it refers to a gene that doesn't exist in mice.
Researchers were able to generate fertilized northern white rhinoceros eggs, according to Mashable.
Former Orig3n employees raise concerns about its testing at Bloomberg Businessweek.
In PLOS this week: microRNA expression changes in hepatocellular carcinoma, real-time PCR-based approach for diagnosing schistosomiasis, and more.